Working towards improving outcomes of lung transplantations with PulmoStem
Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, today announced that it has joined the research project Centre for Advanced Medical Products (CAMP), a consortium funded by a SEK 48 million grant from the Swedish innovation agency Vinnova. In this partnership they will work to improve the outcome of lung transplantations using Amniotics’ stem cell therapy product PulmoStem™.
CAMP is working nationally to build infrastructures and technologies to pave the way for development and commercialization of efficacious gene and cell therapy pharmaceuticals, known as Advanced Therapy Medicinal Products (ATMPs) in the EU. To realise the potential of ATMPs for patients and society, CAMP works to build stronger partnerships between universities, healthcare and industry to ensure effective translation of Swedish research.
“Lung transplantation is the only option for end-stage lung disease. However, only 20 percent of donated lungs are usable for transplantation. The collaboration with CAMP will provide valuable scientific capabilities in our work to show that PulmoStem™ is able to restore damaged and discarded donor lungs and thereby significantly increase the number of lungs available for transplantation,” says Amniotics’ CEO Kåre Engkilde. “We have worked together with Professor Sandra Lindstedt Ingemansson this past year and look forward to expand our collaboration with her and her team at Skåne University Hospital through CAMP.”
“We believe that PulmoStem™ may be an important candidate to help patients suffering from Acute Lung Injury by making more donated lungs suited for transplantation and we are grateful to be able to continue our work with Amniotics and the organization of CAMP to investigate this further,” says Professor Sandra Lindstedt Ingemansson, Skåne University Hospital.
“Amniotics will be a great addition to the CAMP family. Their clinical experience during the pandemic gives them a unique position to accelerate ATMP based solutions to patients with lung disorders for which treatment options are currently limited. We look forward to working with Amniotics and to results in the Amniotic derived cell therapy project”, says Jukka Lausmaa.
Read more about Amniotics in our previous news article ”Amniotics AB pioneer in-house ATiMP production”
Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital, the company is pioneering the harvesting and propagation of tissue specific neonatal MSC. These stem cells have unique properties for applications in regenerative medicine. Amniotics also has an, by Läkemedelsverket (The Swedish Medical Products Agency), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs. Amniotics (publ) has its headquarter in Lund, Sweden.
Amniotics is listed at Nasdaq First North Growth Market in Stockholm. Redeye AB is the company’s Certified Adviser on First North, firstname.lastname@example.org, telephone: +46 (0) 8 121 576 90. Learn more at www.amniotics.com.
CAMP (Centre for Advanced Medical Products) is a Vinnova funded project focusing on the science and technology required to translate Advanced Therapy Medicinal Products (ATMPs) from lab to clinic, including bioprocess development, GMP production and logistics. CAMP drives collaboration between researchers, GMP competent resources, industry and hospitals.
CAMP will receive SEK 48 million (USD 5 million) between 2018 and 2023. This is an important part of the SEK 320 million investment the Swedish government is making to bring Sweden to a world leader position in advanced biological medicines.